# A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

> **NCT01073293** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1054 (actual)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **BIOLOGICAL:** V503 Vaccine
- **BIOLOGICAL:** REPEVAX™ (Concomitant)
- **BIOLOGICAL:** REPEVAX™ (Non-concomitant)

## Key facts

- **NCT ID:** NCT01073293
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-22
- **Primary completion:** 2011-06-16
- **Final completion:** 2011-06-16
- **Target enrollment:** 1054 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073293, "A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01073293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*